Form 4: Esperion Therapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
John B. Harlow Jr., Chief Commercial Officer of Esperion Therapeutics, Inc., reported a transaction in 424,536 shares of common stock on July 13, 2026.
Summary
- Disposition to the issuer: disposed of 424,536 Common Stock on July 13, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
John B. Harlow Jr. — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Disposition to the issuer | Common Stock | 424,536 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Disposition to the issuer (424,536 shares) |
Keywords
insider transaction, Form 4, ESPR, Esperion Therapeutics, Inc., neutral, John B. Harlow Jr.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.